ARA-290 Peptide

ARA-290, also known as cibinetide, is a synthetic 11-amino-acid peptide derived from the structure of erythropoietin (EPO). Unlike EPO, it was designed to activate tissue-protective signaling without stimulating red-blood-cell production.

Research Overview

Research on ARA-290 has focused particularly on neuropathic pain, nerve protection, inflammation, and tissue repair. Animal studies have reported reductions in pain-related behaviors, while small human clinical studies have investigated ARA-290 in conditions including diabetic neuropathy and sarcoidosis-associated small-fiber neuropathy.

A Phase 2 study in people with type 2 diabetes and painful neuropathy reported improvements in neuropathic symptoms and some metabolic measures after 28 days of treatment, with no potential safety issues identified during that study. However, these results come from relatively small clinical studies and do not establish ARA-290 as an approved treatment.

Product Information

Product: ARA-290 / Cibinetide
Type: Synthetic peptide
Structure: 11-amino-acid peptide
Research areas: Neuropathy, neuroprotection, inflammation and tissue-protection pathways
Form: Typically supplied as lyophilized powder for research purposes
Intended use: Research use only

ARA-290 interacts with the innate repair receptor (IRR), making it a promising candidate in research related to chronic inflammation, neuropathic pain, and autoimmune conditions.

Product Details:

Peptide: ARA-290
Purity: >98%
Form: Lyophilized powder
Quantity: 10mg per vial
Storage: Store at -4°F (-20°C). After reconstitution, refrigerate at 36–46°F (2–8°C) and use within 30 days.
Grade: Research use only. Not for human consumption or therapeutic use.

Potential Research Applications:

Anti-inflammatory pathway studies
Neuropathic pain models
Tissue protection and repair research
Innate repair receptor (IRR) exploration

THIS IS NOT FOR HUMAN CONSUMPTION. SOLD FOR RESEARCH ONLY!

FAQ

What is ARA-290?
ARA-290, also called cibinetide, is a synthetic peptide derived from the structure of erythropoietin and investigated for tissue-protective and anti-inflammatory signaling.

What is ARA-290 studied for?
Research has investigated ARA-290 in areas including neuropathic pain, small-fiber neuropathy, nerve protection and tissue repair.

Does ARA-290 help with neuropathy?
Some early clinical studies reported improvements in neuropathic symptoms, but the evidence remains limited and further research is needed to establish its clinical effectiveness.

Is ARA-290 the same as erythropoietin?
No. ARA-290 was designed from the structure of EPO but is a separate peptide and was developed to target tissue-protective signaling without stimulating erythropoiesis.

Is ARA-290 FDA approved?
It should not be marketed as an FDA-approved treatment. If you’re selling it as a research product, clearly identify it as for research use only and avoid presenting it as a treatment for neuropathy or other medical conditions.

Is ARA-290 safe?
Safety data in humans are limited. Early clinical studies reported no major safety issues within the study populations and treatment periods, but this does not establish long-term safety or safety for general use.

ARA-290, ARA 290 peptide, ARA-290 benefits, ARA-290 research, ARA-290 peptide research, ARA-290 neuropathy, ARA-290 safety, ARA-290 cibinetide, cibinetide peptide